Back to Search Start Over

A Brief Screening Tool for Opioid Use Disorder: EMPOWER Study Expert Consensus Protocol.

Authors :
You DS
Mardian AS
Darnall BD
Chen CA
De Bruyne K
Flood PD
Kao MC
Karnik AD
McNeely J
Porter JG
Schwartz RP
Stieg RL
Mackey SC
Source :
Frontiers in medicine [Front Med (Lausanne)] 2021 Mar 31; Vol. 8, pp. 591201. Date of Electronic Publication: 2021 Mar 31 (Print Publication: 2021).
Publication Year :
2021

Abstract

Growing concerns about the safety of long-term opioid therapy and its uncertain efficacy for non-cancer pain have led to relatively rapid opioid deprescribing in chronic pain patients who have been taking opioid for years. To date, empirically supported processes for safe and effective opioid tapering are lacking. Opioid tapering programs have shown high rates of dropouts and increases in patient distress and suicidal ideation. Therefore, safe strategies for opioid deprescribing that are more likely to succeed are urgently needed. In response to this demand, the EMPOWER study has been launched to examine the effectiveness of behavioral medicine strategies within the context of patient-centered opioid tapering in outpatient settings (https://empower.stanford.edu/). The EMPOWER protocol requires an efficient process for ensuring that collaborative opioid tapering would be offered to the most appropriate patients while identifying patients who should be offered alternate treatment pathways. As a first step, clinicians need a screening tool to identify patients with Opioid Use Disorder (OUD) and to assess for OUD severity. Because such a tool is not available, the study team composed of eight chronic pain and/or addiction experts has extended a validated screening instrument to develop a brief and novel consensus screening tool to identify OUD and assess for OUD severity for treatment stratification. Our screening tool has the potential to assist busy outpatient clinicians to assess OUD among patients receiving long-term opioid therapy for chronic pain.<br />Competing Interests: RPS reports serving as a consultant to Verily Life Sciences, Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 You, Mardian, Darnall, Chen, De Bruyne, Flood, Kao, Karnik, McNeely, Porter, Schwartz, Stieg and Mackey.)

Details

Language :
English
ISSN :
2296-858X
Volume :
8
Database :
MEDLINE
Journal :
Frontiers in medicine
Publication Type :
Academic Journal
Accession number :
33869240
Full Text :
https://doi.org/10.3389/fmed.2021.591201